Can HEPZATO move beyond uveal melanoma? Delcath begins major metastatic breast cancer test
Delcath has dosed the first patient in the DELUMA Phase 2 trial, testing HEPZATO for liver-dominant HER2-negative metastatic breast cancer.
Pharma & Biotech